Trogenix
Trogenix is developing precision genetic medicines for aggressive solid tumors using its proprietary Odysseus® platform, built around Synthetic Super-Enhancers (SSEs) that activate only in diseased cell states. The therapy uses AAV vectors to deliver a cytotoxic enzyme and IL-12 directly into the tumor, killing cancer cells while stimulating long-term immune memory. Its lead program targets glioblastoma (GBM), an area of extremely high unmet medical need.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Traditional cancer treatments, particularly for aggressive solid tumors like glioblastoma (GBM), offer limited efficacy and often result in chronic disease management rather than cure. Current therapies lack the selectivity to destroy cancer cells without harming healthy tissue, and patients face high rates of recurrence due to tumor plasticity and immune evasion.
Solution
Trogenix is developing precision genetic medicines using its proprietary Odysseus® platform, built around Synthetic Super-Enhancers (SSEs)—engineered DNA elements that are activated only in diseased cell states. These SSEs act as docking stations for transcription factors uniquely expressed in aggressive cancer cells, enabling highly selective gene control. The therapy uses AAV vectors to deliver two payloads directly into the tumor: one produces an enzyme that converts an oral prodrug into a cytotoxic agent, while the other generates IL-12 to stimulate an immune response. This "Trojan Horse" approach kills cancer cells, activates the immune system, and establishes long-term immunological memory to prevent recurrence. The platform is designed to be adaptable across multiple cancer types and potentially other disease areas.
Target Audience
Primary customers are oncology patients with aggressive solid tumors, beginning with glioblastoma (GBM), as well as healthcare providers and clinical researchers focused on cancer immunotherapy and precision medicine.
Features
- Synthetic Super-Enhancers (SSEs) engineered to respond to transcription factors unique to aggressive cancer and therapy-resistant states
- Self-dosing control where treatment intensity automatically scales with the number of diseased cells present
- Dual payload delivery combining targeted cell killing with immune system activation via IL-12
- Compact SSE design enables packaging into AAV vectors alongside therapeutic payloads
- Built-in safety mechanism where activity extinguishes as cancer cells are killed or exit their aggressive state
- Modular platform enables rapid deployment and engineering of new genetic medicines across cancer types
- Platform extends beyond oncology to regenerative medicine, tissue repair, and age-related diseases